Liver cancer drug combo vs. local therapy: trial ends early
NCT ID NCT05537402
First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times
Summary
This study aimed to compare two standard treatments for people with large intermediate-stage liver cancer that cannot be surgically removed. One group would receive a combination of two immunotherapy drugs (atezolizumab and bevacizumab), while the other would receive local treatments like chemoembolization or radioembolization. The trial was terminated after enrolling only one participant, so no meaningful results were obtained.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
Dallas, Texas, 75390, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
atezolizumab and bevacizumab (immunotherapy drugs)
What this could lead to
If successful, this could show that a drug combination works better than local treatments for certain liver cancer patients.
What could go wrong
The trial was terminated after enrolling only 1 person, so results are not available. It is too early to draw any conclusions.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.